BioSpace News Archive

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the third quarter ended September 30, 2021, and provided a corporate update.

Thermo Fisher Scientific Inc. announced that it has priced an offering of €2.8 billion aggregate principal amount of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific B.V., its indirect, wholly owned finance subsidiary.

Inhibrx, Inc.Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, reported financial results for the third quarter of 2021 and provided an update on recent corporate highlights.

INOVIO, a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer, and HPV-associated diseases, reported financial results for the quarter ended September 30, 2021.

CTI BioPharma Corp. announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company’s Amended and Restated 2017 Equity Incentive Plan and material to the employees’ acceptance of employment with the company.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, reported financial results for the third quarter ended September 30, 2021 and provided a business update.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2021.

Ligand Pharmaceuticals Incorporated reported financial results for the three and nine months ended September 30, 2021 and provided an operating forecast and program updates.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals GmbH (ESTEVE) to commercialize INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany.